Falette, N.Paperin, M. P.Treilleux, I.Gratadour, A. C.Peloux, N.Mignotte, H.Tooke, N.Löfman, E.Inganäs, M.Bremond, A.Ozturk, M.Puisieux, A.2016-02-082016-02-0819980008-5472http://hdl.handle.net/11693/25472The most important subgroup of breast cancer patients for which reliable prognostic factors are needed are women without axillary lymph node involvement. Although overall, these patients have a good prognosis, it is known that 20-30% will experience a recurrence of the disease. To determine the prognostic significance of P53 tumor suppressor gene mutation, specimens from 113 primary breast cancers were evaluated for the presence of P53 alterations, as detected by cDNA sequencing of the entire coding sequence of the gene. The median follow-up for patients was 105 months. P53 gene mutation was an independent prognostic marker of early relapse and death. Our results suggest that P53 gene mutations could be an important factor to identify node-negative patients who have a poor prognosis in the absence of adjuvant therapy. Prospective studies should be designed to determine which therapy should be performed in this subgroup of patients.EnglishProtein p53Breast cancerCancer stagingGene mutationMajor clinical studyArticle